(Q35058929)

6 August 2017

1 reference

title

ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects (English)

1 reference

6 August 2017

Yoon-Jeong Park

1

1 reference

6 August 2017

Jun-Feng Liang

2

1 reference

6 August 2017

Hui Song

3

1 reference

6 August 2017

Yong Tao Li

4

1 reference

6 August 2017

Sarita Naik

5

1 reference

6 August 2017

Victor C Yang

6

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Advanced Drug Delivery Reviews

6 August 2017

published in

1 reference

6 August 2017

volume

55

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

251-265

1 reference

Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Oral delivery of proteins: progress and prognostication

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Water-based nanoparticulate polymeric system for protein delivery: permeability control and vaccine application

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Bioconjugation in pharmaceutical chemistry.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

New insights on thrombolytic treatment of acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Activation and stabilization of asparaginase by anti-asparaginase IgG and its Fab

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Chemical modification of enzyme molecules to improve their characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Immunoconjugates of soybean Bowman-Birk protease inhibitor as targeted antitumor polymeric agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Antibody-directed therapies for hematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Antibody-directed enzyme prodrug therapy (ADEPT): a review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Delivery system for targeted thrombolysis without the risk of hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

A novel approach for delivery of enzyme drugs: preliminary demonstration of feasibility and utility in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

The potential mechanism for the effect of heparin on tissue plasminogen activator-mediated plasminogen activation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

A recombinant prodrug type approach for triggered delivery of streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Basic local alignment search tool

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Tissue-type plasminogen activator: variants and crystal/solution structures demarcate structural determinants of function

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4-.ANG. resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Binding of a de novo designed peptide to specific glycosaminoglycans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

Molecular modeling of protein-glycosaminoglycan interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

28 Molecular design and modeling of protein—heparin interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2802%2900181-3

7 January 2021

10.1016/S0169-409X(02)00181-3

Identifiers

DOI

1 reference

release_5ulojxxvx5he5nai24et7vthxy

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5ulojxxvx5he5nai24et7vthxy

24 November 2022

mapped directly with Wikidata item

1 reference